SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Prevalence of chronic pain or analgesic use in children and young people and its long-term impact on substance misuse, mental illness, and prescription opioid use: a retrospective longitudinal cohort study

Lambarth, A; Katsoulis, M; Ju, C; Warwick, A; Takhar, R; Dale, C; Prieto-Merino, D; Morris, A; Sen, D; Wei, L; et al. Lambarth, A; Katsoulis, M; Ju, C; Warwick, A; Takhar, R; Dale, C; Prieto-Merino, D; Morris, A; Sen, D; Wei, L; Sofat, R (2023) Prevalence of chronic pain or analgesic use in children and young people and its long-term impact on substance misuse, mental illness, and prescription opioid use: a retrospective longitudinal cohort study. The Lancet Regional Health - Europe, 35. p. 100763. ISSN 2666-7762 https://doi.org/10.1016/j.lanepe.2023.100763
SGUL Authors: Lambarth, Andrew Trevor

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (767kB) | Preview
[img] Microsoft Word (.docx) (Supplementary Material) Published Version
Available under License Creative Commons Attribution.

Download (847kB)

Abstract

Background Epidemiological studies suggest chronic and recurrent pain affects around a quarter of children, while 8% report intense and frequent pain. The long-term implications of chronic pain in childhood are uncertain. Using electronic health records (EHRs) we used both disease codes and medicines prescription records to investigate the scale of chronic pain and long-term analgesic use in children and young people (CYP), and if chronic pain and/or use of analgesic medicines at an early age is associated with substance misuse, use of prescription opioids, and poor mental health in adulthood. Methods We conducted a cohort study using data from IQVIA Medical Research Data UK. We identified individuals aged 2–24 with exposure to either a diagnostic code indicating chronic pain (diagnosis-exposed), repeat prescription for medicines commonly used to treat pain (prescription-exposed), or both. Follow-up began at 25, and the unexposed population acted as comparators. We calculated hazard ratios (HR) for mental health and substance misuse outcomes, and rate ratios (RR) for opioid prescriptions in adulthood. Additionally, we investigated which diagnoses, if any, were over-represented in the prescription-exposed subgroup. Findings The cohort constituted 853,625 individuals; 146,431 had one or more of the exposures of interest (diagnosis-exposed = 115,101, prescription-exposed = 20,298, both-exposed = 11,032), leaving 707,194 as comparators. Median age at index exposure was 18.7 years (IQR 14.7–22.3). On average during follow-up, the pooled exposed group had, respectively, a 31% and 17% higher risk of adverse mental health and substance misuse outcomes (adjusted HR [95% CI] of 1.31 [1.29–1.32] and 1.17 [1.11–1.24]). Exposed individuals also received prescription opioids at double the rate of unexposed individuals on average during follow-up (adjusted RR 2.01 [95% CI 1.95–2.10]). Outcomes varied between exposure subgroups, with prescription- and both-exposure tending to have worse outcomes. Unlike these two subgroups, in the diagnosis-exposed subgroup we did not detect a greater risk of substance misuse. Interpretation Chronic pain in CYP is associated with increased prescription opioid use and adverse mental health outcomes in adulthood, as is repeat prescription for analgesic medicines, but only the latter is also associated with substance misuse in adulthood. It is essential to avoid the harms of under-treating pain in CYP while giving due consideration to the risks posed by analgesic medicines. Early recognition of chronic pain in CYP and utilising non-pharmacological management options may help minimise overprescribing, and long-term reliance on dependence-forming-drugs.

Item Type: Article
Additional Information: Copyright © 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: The Lancet Regional Health - Europe
ISSN: 2666-7762
Language: en
Dates:
DateEvent
1 December 2023Published
15 November 2023Published Online
12 October 2023Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MR/W002566/1UK Research and Innovationhttp://dx.doi.org/10.13039/100014013
MR/W002566/1Versus Arthritishttp://dx.doi.org/10.13039/501100012041
220558/Z/20/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
URI: https://openaccess.sgul.ac.uk/id/eprint/115927
Publisher's version: https://doi.org/10.1016/j.lanepe.2023.100763

Actions (login required)

Edit Item Edit Item